Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people begin to notice the effects of semaglutide within the first one to two weeks of starting treatment, though the changes are gradual. Appetite tends to quieten before the scales move. Meaningful weight loss usually becomes visible over one to three months, as the dose increases and the medicine reaches its working level in your system. Semaglutide is a prescription-only medicine; a clinician assesses whether it is appropriate for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The earliest effect most people describe is not weight loss) it is a quieter internal voice telling them to eat. Semaglutide works as a GLP-1 receptor agonist, mimicking a gut hormone that signals fullness to the brain and slows how quickly food leaves the stomach. That mechanism kicks in from the very first dose, even at the low 0.25 mg starting level.
Within the first seven to fourteen days, you may find you leave food on the plate without trying, feel satisfied after smaller portions, or simply think about food less. Some people also notice their blood sugar feels steadier, less of the mid-afternoon dip that sends you hunting for biscuits.
What you are unlikely to notice yet: significant weight change. The starting dose is calibrated to let your body adjust, not to drive immediate loss. Nausea, if it appears, tends to peak in this window and eases for most people before the four-week mark. The full range of effects semaglutide produces builds across the whole titration journey, not in a single week.
Practical tip: keep your pen in the fridge door where you will see it on injection day, building a consistent weekly routine matters more than most people expect, because steady drug levels underpin steady effects.
By the time you reach your first dose increase) typically from 0.25 mg to 0.5 mg at around week five, you are likely to see the number on the scales start to move. This is when the appetite reduction translates into a meaningful calorie deficit, day after day.
For most people on semaglutide, the rate of weight loss is not dramatic in any single week. Studies published in the New England Journal of Medicine recorded an average loss of around 15% of body weight over the 68-week STEP 1 trial, which works out to a steady, sustained reduction rather than a rapid drop. In the first three months, a loss of three to five percent of starting body weight is a reasonable expectation, depending on your starting point, diet and activity.
The dose continues to step upward: 0.5 mg, then 1.0 mg, then 1.7 mg, then 2.4 mg at the standard Wegovy schedule, each increase guided by your prescriber. If you want to understand exactly when Wegovy's effects are felt at each dose level, that page goes into more detail on the titration timeline. Energy levels often improve in this phase as eating patterns settle. Digestive side effects, if they returned at the dose step, usually settle again within a couple of weeks.
Once you reach the 2.4 mg maintenance dose, the rate of weight loss typically continues but the pace of early change levels off. This is normal and expected, the body adapts. Clinical evidence from the STEP programme, reviewed by the NHS medicines information for semaglutide, supports continued weight loss across the full 68-week treatment period, with the greatest total reduction seen in people who stay on the full course alongside dietary changes.
Other effects that develop over this longer window include improved blood-pressure readings, better cholesterol profiles, and (for those who had prediabetes) improvements in blood-sugar control. These are not things most people feel day to day, but they matter clinically.
A small number of people find the effects plateau earlier. If less than 5% of body weight has been lost after six months at the maintenance dose, your prescriber will review whether continuing is appropriate, this is a standard clinical checkpoint, not a failure. The broader physical effects of semaglutide extend well beyond the number on the scales, and that fuller picture is worth understanding before starting.
For those considering private treatment, how and where to access Wegovy in the UK is a practical question that runs alongside the clinical one. The consultation with a prescriber is where both get answered. If you have specific questions about how semaglutide works as a medicine, or want a broader overview of Wegovy as a treatment option, those pages cover the mechanism and licensing in depth.
Semaglutide's effects are not immediate, but they are cumulative. The readers who get the most from treatment are usually those who understand that the first fortnight is adjustment, the first three months are momentum, and the months beyond that are where the clinical results are built. If you are ready to find out whether you are a suitable candidate, starting a free consultation with our prescribers is the place to begin.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.